<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02593383</url>
  </required_header>
  <id_info>
    <org_study_id>zhaoke-2015-02</org_study_id>
    <nct_id>NCT02593383</nct_id>
  </id_info>
  <brief_title>Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne</brief_title>
  <official_title>A Placebo Control, Multicenter, Randomized, Double Blind, Multi-formula Groups, and Parallel Phase Ⅰb+Ⅱa Study Evaluating the Safety and Efficacy of Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluate the safety and efficacy of Compound Adapalene and Clindamycin Hydrochloride Gel in
      treatment of chinese patients with acne.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of patients with deceased acne lesions at the treatment end (Day 85±3) in each group;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGA classification change</measure>
    <time_frame>12 weeks</time_frame>
    <description>The improvement of IGA （investigator general Assess）Classification at the treatment end (Day 85±3) in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment success rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>The treatment success rate at the treatment end (Day 85±3) in each group; calculation methods:number of patients with IGA assessment improved to level 0 to level 1/ total number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK</measure>
    <time_frame>12 weeks</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK</measure>
    <time_frame>12 weeks</time_frame>
    <description>peak plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Treat group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: 0.1% Adapalene + 1% Clindamycin Hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: 0.1% Adapalene + 2% Clindamycin Hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3: 0.05% Adapalene + 0.5% Clindamycin Hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4: 0.05% Adapalene + 1% Clindamycin Hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Group: Blank Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene + Clindamycin Hydrochloride</intervention_name>
    <description>0.1% Adapalene + 1% Clindamycin Hydrochloride</description>
    <arm_group_label>Treat group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene + Clindamycin Hydrochloride</intervention_name>
    <description>0.1% Adapalene + 2% Clindamycin Hydrochloride</description>
    <arm_group_label>Treatment group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene + Clindamycin Hydrochloride</intervention_name>
    <description>0.05% Adapalene + 0.5% Clindamycin Hydrochloride</description>
    <arm_group_label>Treatment group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene + Clindamycin Hydrochloride</intervention_name>
    <description>0.05% Adapalene + 1% Clindamycin Hydrochloride</description>
    <arm_group_label>Treatment group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age from 18 to 40 years old, female or male;

          2. Class I-III of Acne vulgaris according to the International Modified PILLSBURY
             Classification;

          3. Patients voluntarily take part in the study and sign the ICF.

        Exclusion Criteria:

          1. The subject is known to be allergic to adapalene, clindamycin hydrochloride,
             clindamycin, and / or any components of gel excipient;

          2. Patients with secondary acne including occupational acne and corticosteroid-induced
             acne;

          3. The affected skin has other concomitant lesion (such as solar dermatitis, psoriasis,
             seborrheic dermatitis, eczema and extremely severe acne) which may impact the efficacy
             evaluation;

          4. Subject has the history of regional enteritis, ulcerative colitis or
             antibiotic-associated colitis;

          5. Patient has history of severe cardiac disease and hypertension;

          6. Patient has severe liver and kidney diseases with AST/ALT more than twice upper
             limitation, or Cr, total cholesterol and triglycerides above normal range;

          7. Patients with severe endocrine diseases, blood diseases, and neuropsychiatric
             disorders;

          8. Patients are known to have severe immune dysfunction, or need long-term use of
             corticosteroids or immunosuppressive agents;

          9. Pregnant or breastfeeding women, or unwilling to take effective contraceptive measures
             during the study;

         10. Alcoholic patients or drug abusers;

         11. Patient has used other acne drugs topically within 2 weeks before the study start;

         12. Patient has been administered with victoria A acid, vitamins, and antibiotics within 4
             weeks before the study start;

         13. Patient has participated in other study within 3 months before the study start;

         14. The subject is not fit to take part in this study in the judgment of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heng GU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Dermatology, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heng GU, MD</last_name>
    <phone>025-85478999</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pengcheng MA, Ph. D.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Dermatology, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heng GU, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2015</study_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

